Osteoporosis is rarely well managed by a single intervention. The condition reflects the interaction of nutrition, hormonal status, mechanical loading, and the cellular biology of bone formation and breakdown. At the London Osteoporosis Clinic, the clinical pathway is reversal-first: rebuild bone where rebuilding is possible, consolidate the gains, and use bisphosphonates last, if at all.
- Treatment that addresses only the pharmacological element of osteoporosis tends to deliver short-term fracture risk reduction without changing the underlying trajectory.
- Two categories of medication are in use: anti-resorptive agents (which slow bone loss) and anabolic agents (which actively stimulate bone formation).
- In the reversal-first pathway, anabolic agents are used in the rebuilding phase; bisphosphonates are used selectively in the consolidation phase — not as a default first step.
- Holistic foundations — nutrition, loading exercise, hormonal status, secondary cause investigation — operate continuously alongside any pharmacological treatment.
Osteoporosis is rarely well managed by a single intervention. The condition reflects the interaction of nutrition, hormonal status, mechanical loading, and the cellular biology of bone formation and breakdown. Treatment that addresses one element of that picture — typically the pharmacological one — and ignores the rest tends to deliver short-term reductions in fracture risk without changing the underlying trajectory. At the London Osteoporosis Clinic, the clinical pathway is reversal-first: rebuild bone where rebuilding is possible, consolidate the gains, and use bisphosphonates last, if at all. Medications, particularly anabolic agents, have a defined and useful place within this pathway. They are not the cornerstone of it.
Two categories of medication
Two categories of osteoporosis medication are in routine clinical use: anti-resorptive agents, which slow bone breakdown, and anabolic agents, which actively stimulate bone formation. Each category contains drugs with distinct mechanisms, distinct risk profiles, and distinct positions in the pathway.
Anti-resorptive agents
Bisphosphonates (alendronate, risedronate, zoledronate) slow bone resorption and stabilise density. They are effective at reducing fracture risk in patients at meaningful risk. Long-term use carries small but real risks — atypical femoral fractures and osteonecrosis of the jaw — which is one reason treatment duration is typically limited and reviewed.
Selective oestrogen-receptor modulators such as raloxifene mimic some effects of oestrogen in bone. They are generally well tolerated; they carry an increased risk of thromboembolism that needs consideration in the right patient.
Denosumab is a monoclonal antibody against RANK ligand that inhibits osteoclast development. It is effective; it requires careful management at discontinuation, because abrupt cessation can produce rapid bone loss and vertebral fractures.
Anabolic agents
Teriparatide is a synthetic fragment of parathyroid hormone that stimulates bone formation. It is one of the small number of agents that actively builds bone rather than slowing its loss, and is therefore central to the reversal-first phase of treatment in patients for whom it is appropriate. It is typically used for a defined period — up to two years — and is followed by a consolidation strategy.
Romosozumab inhibits sclerostin and has both anabolic and anti-resorptive properties. It is used for short periods in patients at high fracture risk; cardiovascular risk needs to be weighed in selection.
Where these sit in the LOC pathway
In the reversal-first pathway, anabolic agents are the pharmacological tool of the reversal phase, used selectively and under consultant supervision. Anti-resorptive agents — bisphosphonates in particular — have their place in the consolidation phase, where the priority is to protect the bone density already rebuilt; and in patients in whom anabolic agents are contraindicated or where short-term anti-resorption is clinically necessary. They are not, in this clinical approach, the default first treatment.
Holistic foundations
Pharmacological treatment sits alongside the elements of the pathway that operate continuously rather than within a defined treatment window. These are not alternative therapies — they are the conditions in which medical treatment, where used, has its best chance of producing a lasting result.
Nutrition is foundational. Adequate protein supports the collagen matrix upon which bone mineral is deposited. Calcium, vitamin D, vitamin K2, and magnesium each have documented roles in bone metabolism. Reducing or eliminating alcohol and avoiding tobacco supports the wider metabolic environment in which bone is maintained.
Loading exercise — weight-bearing and resistance work — provides the mechanical signal that tells the skeleton structural strength is required. It is one of the most direct biological inputs for bone formation and is not replaceable by pharmacological means.
Hormonal status, particularly across the menopausal transition, has a direct effect on the rate of bone resorption. Addressing hormonal imbalances — through lifestyle changes or, where appropriate, hormone replacement therapy (HRT) — is a practical component of a structured osteoporosis management plan.
Secondary causes of bone loss — coeliac disease, prolonged steroid use, hyperthyroidism, malabsorption syndromes, prolonged proton-pump-inhibitor use — should be identified and addressed before or alongside any pharmacological treatment. Prescribing a drug on top of an unaddressed cause is treating the measurement rather than the condition.
The patients who do best over time are those in whom the full picture has been addressed — not just the T-score. We often see patients who have been on bisphosphonates for years without ever having had a structured assessment of why bone loss occurred in the first place. The reversal-first pathway changes that sequence. Where rebuilding is possible, we pursue it first. Where bisphosphonates are appropriate — as a consolidation step or where anabolic therapy is contraindicated — they have a place. But they are a tool in the pathway, not the pathway itself. If you would like a consultant-led assessment or information about our structured treatment pathways, our team can help.
The right context for treatment
Pharmacological treatment for osteoporosis works best when it is one part of a wider clinical picture, not the whole of it. The reversal-first pathway makes that explicit: rebuild bone where possible, protect those gains, and reach for bisphosphonates last, if at all.
A structured specialist assessment considers the full biological picture — the hormonal, metabolic, nutritional, and inflammatory landscape in which bone is being formed or lost — before any pharmacological recommendation is made. The goal is not to treat a number on a scan. It is to restore the conditions in which the skeleton can maintain itself.
Frequently Asked Questions
What does “reversal-first” mean in practice?
It means that where rebuilding bone is clinically possible, the pathway pursues that first — using anabolic agents such as teriparatide — before reaching for anti-resorptive drugs whose mechanism is to slow loss rather than restore it. Once bone has been rebuilt, the consolidation phase may use bisphosphonates to protect the gains. The sequence matters because bone that has been actively rebuilt is structurally different from bone that has merely been slowed in its decline.
Can teriparatide and bisphosphonates be used together?
Generally no — they are not used in combination, because bisphosphonates can blunt the anabolic effect of teriparatide. The standard sequence in the reversal-first pathway is: anabolic phase first (teriparatide or romosozumab), followed by a consolidation phase with an anti-resorptive agent to protect the bone density gained. Your consultant will advise on the appropriate sequence for your specific case.
How long does anabolic treatment last?
Teriparatide is typically prescribed for up to two years. Romosozumab is used for up to 12 months. Both are followed by a planned transition to a consolidation strategy — usually an anti-resorptive agent — to prevent loss of the bone gained during the anabolic phase. The entire sequence is planned at the outset rather than decided reactively, which is one advantage of a structured pathway approach.
Medically reviewed by Dr. Taher Mahmud, Consultant Rheumatologist and Co-Founder, London Osteoporosis Clinic. Dr. Mahmud has over 25 years of clinical experience in bone health and osteoporosis management.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified clinician before starting, stopping, or changing any prescribed medication.
For further assessment or personalised guidance, please visit www.LondonOsteoporosisClinic.com.
